REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:
An audio webcast of the fireside chat presentation will be available on the investors’ page of the Coherus website at http://investors.coherus.com. Please access the website prior to the start of the presentation to ensure a timely connection to the webcast. The webcast will be archived on the Coherus website for 30 days.
Coherus Contact Information:
Marek Ciszewski, SVP Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.88 |
| Daily Change: | -0.01 -1.65 |
| Daily Volume: | 607,328 |
| Market Cap: | US$102.130M |
May 12, 2025 March 10, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
